Poster Abstracts • OFID 2018:5 (Suppl 1) • S123 sensitivity and specificity for CRP were found to be 0.64 (95% CI 0.46-0.80) and 0.87 (95% CI 0.75-0.93) with AUROC of 0.85 (95% CI0.82-0.88). Pooled sensitivity and specificity for PCT were 0.74 (95% CI 0.62-0.83) with AUROC of 0.84 (95% CI 0.81-0.87).
Background. To evaluate the clinical characteristics and outcomes of patients with naïve septic arthritis caused by methicillin-resistant Staphylococcus aureus (MRSA).
Methods. We conducted a retrospective review of adult patients with naïve septic arthritis at three tertiary-care hospitals from 2005 through 2017.
Results. Of the 101 patients with S. aureus naïve septic arthritis, 39 (38.6%) was identified MRSA. Compared with patients with methicillin-susceptible Staphylococcus aureus (MSSA), patients with MRSA presented more frequently with nosocomial infection (1.6% vs. 17.9%; P = 0.005), and inappropriate antibiotics within 48h (0% vs. 74.4%; P < 0.001). The overall 30-day mortality was 4% and tended to be higher in MRSA group (1.6% vs. 7.7%; P = 0.296). The treatment failure was 23.8%, which was higher in the MRSA group (35.9% vs. 16.1%; P = 0.031). The independent risk factors for treatment failure were end-stage of renal disease with hemodialysis (odds ratio [OR] = 32.073; 95% confidence interval [CI]: 2.669-385.372; P = 0.006) and antibiotics duration less than 6 weeks (OR = 4.987; 95% CI: 1.204-20.662; P = 0.027) Conclusion. MRSA septic arthritis was associated with more frequent nosocomial infection and delayed treatment compared with MSSA septic arthritis. Antibiotic therapy, for less than 6 weeks, may be cautioned for S aureus septic arthritis until better outcomes are assured.
Disclosures. All authors: No reported disclosures. Background. Current guidelines for treatment of prosthetic joint infection (PJI) suggest a combination of intravenous (IV) antibiotics for 2-6 weeks and oral antibiotics for 3-6 months. However, recent studies did not find significant benefits from prolonged use of antibiotics for patients with PJI. We conducted a systemic review and meta-analysis to assess the outcomes of short-and long-term antibiotics in patients with PJI.
Comparison of Short and Long Courses of Antibiotics in Patients with
Methods. We designed three queries to retrieve literature of PJI from PubMed and Embase databases until December 2017. Each query comprised medical subject headings, title/abstract keywords, and exclusion terms. Two reviewers independently screened literature for three rounds and disagreements were resolved by a third reviewer. Quality of a cohort study and that of a randomized control trial (RCT) were assessed by Newcastle-Ottawa Quality Assessment Form and a modified Jadad scale respectively.
Results. A total of 3,309 studies were retrieved, and nine observation studies and one RCT were included for final analysis (Figure 1 ). Nine of the 10 studies investigated total hip arthroplasty and/or total knee arthropathy, while one study further included shoulder, elbow, and ankle arthroplasty. Five studies focused on patients receiving debridement and implant retention (DAIR) procedure, three studies on staged exchange arthroplasty (SEA), and two studies on mixed procedures. Eight of the 10 studies were graded as good or fair quality. All of the 10 studies found equivalent outcomes in patients prescribed with short-and long-term antibiotics, regardless of IV or oral form of antibiotics. The aggregate odds ratio (OR) in our meta-analysis was 1.04 (95% CI, 0.70, 1.55), showing no significant difference in outcomes between short-term and long-term antibiotics (Figure 2) .
Conclusion.
Our meta-analysis demonstrated that patients prescribed with short-term antibiotics for PJI had similar outcomes when compared with those prescribed with long-term antibiotics. S124 Background. Native joint septic arthritis (NJSA) is commonly caused by Grampositive organisms. Gram-negative NJSA is uncommon, and discussion is usually limited to gonococcal arthritis despite NJSA due to enterobacteriaceae being more prevalent. We aimed to describe the clinical features, treatment, and outcomes of enterobacteriaceae NJSA (ENJSA).
Methods. Cases were obtained from a previously described retrospective cohort of adult NJSA admitted to Middlemore Hospital, Auckland, and New Zealand between January 1, 2009 and December 31, 2014. ENJSA episodes were compared with non-Enterobacteriaceae NJSA (NENJSA).
Results. From 543 NJSA episodes identified, ENJSA were the most frequent Gram-negative group (7%, 36/543) followed by HACEK (25/543), nonfermenters (10/543), Pasteurella (9/543), and Neisseria (5/543). The median age of ENJSA cases was 50 years and 72% were male. Immune compromise was more prevalent in ENJSA (19%, 7/36) than NENJSA (8%, 42/507), P = 0.0341. The most common causative organism for ENJSA was E. coli (10/36), followed by Enterobacter cloacae (8/36) and Klebsiella pneumoniae (6/36). Polymicrobial infection was more common in ENJSA (64%, 23/36) than NENJSA (20%, 99/507), P ≤ 0.0001. All ENJSA cases were monoarticular, and 72% (26/36) affected large joints. Small joint infection was less common in ENJSA (28%, 10/36) than NENJSA (47%, 240/507), P = 0.0247. Osteomyelitis was more common in ENJSA (53%, 19/36) than NENJSA (23%, 116/507), P = 0.0002. Carbapenems and ciprofloxacin were the most commonly utilised antimicrobials for ENJSA. Clinical outcomes were worse for ENJSA, with higher rates of treatment failure (53%, 19/36) than NENJSA (15%, 76/507), P = 0.0001 (although this association did not persist on multivariate analysis of the whole cohort) and longer mean length of stay (23.2 vs. 12.8 days P = 0.0001).
Conclusion. Enterobacteriaceae are an important and poorly described cause of NJSA, associated with immune compromise, large joint infection, polymicrobial infection, treatment failure, and increased hospital length of stay. The optimal management strategy to improve ENJSA outcomes is unknown, but may include more aggressive surgical and longer medical therapy. Further studies of ENJSA are warranted.
Disclosures. All authors: No reported disclosures. Background. Bone and joint infections (BJIs) are common infections managed by infectious diseases specialists. There are increasing data that oral therapy is equivalent to intravenous therapy and is typically preferred by patients. However, there are limited safe oral options to treat some causative pathogens. Tedizolid is an oxazolidinone with broad Gram-positive coverage that in animal studies lacks the hematologic and neurologic toxicity of linezolid.
Safety and Tolerability of Tedizolid as
Methods. We are conducting an open-label single-center trial of oral tedizolid for the treatment of BJIs. The primary outcome of this study is patient safety. Patients are eligible if they have a BJI caused by documented or suspected Gram-positive pathogen and require at least 4 weeks of therapy (up to 12 weeks). Enrolled patients undergo weekly monitoring for neurologic and visual, side effects and weekly hematologic and comprehensive chemistry panel lab monitoring. Patients with peripheral neuropathy and cytopenias are excluded from participation.
Results. To date, we have enrolled 19 subjects (17 (89%) male) with BJIs (11 (58%) hardware associated infection, 5 (26%) osteomyelitis without prosthesis, 3 (16%) prosthetic joint infection). Significant comorbidities include six (32%) with diabetes and one (5%) with systemic lupus. Fourteen (74%) patients have completed therapy, two (11%) remain on therapy, one (5%) withdrew from the study, and two (11%) were lost to follow-up. Mean (median) duration of treatment has been 9.7 (11) weeks with a range of 4-12 weeks. Significant drug-related adverse events occurred in two patients (11%), both with non-life-threatening maculopapular rashes, one of whom required treatment discontinuation. To date, there have been 10/14 (71%) treatment successes. Failures have been associated with previously undetected retained hardware (n = 1), sequestrum requiring surgery (n = 1), and failure to achieve cure after the designated treatment course (n = 2). There have been no cases of cytopenias, peripheral or optic neuropathy.
Conclusion. Tedizolid appears to be a well-tolerated oral antibiotic for the treatment of bone and joint infections for 4 weeks or greater. Clinical failure rates appear roughly similar to that of other oral options. Further study of tedizolid for BJIs is warranted.
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